BioCryst Pharmaceuticals Valuation

Q: What is the Fair Price of BCRX * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

BCRX * (MX$170) is trading below our estimate of [[fair value]] (MX$850.85)

Is BCRX * undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BCRX * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BCRX * (MX$170) is trading below our estimate of fair value (MX$850.85)

Significantly Below Fair Value: BCRX * is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BCRX *?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for BCRX *. This is calculated by dividing BCRX *'s market cap by their current preferred multiple.
What is BCRX *'s n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$1.58b

BCRX * key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.6x
Enterprise Value/EBITDA	-40.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does BCRX *'s PS Ratio compare to its peers?

The above table shows the PS ratio for BCRX * vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	16.9x
LAB B Genomma Lab Internacional. de	1.3x	5.8%	Mex$21.2b
NRIX Nurix Therapeutics	23.8x	29.1%	US$1.5b
BCYC Bicycle Therapeutics	40.5x	52.2%	US$1.6b
2696 Shanghai Henlius Biotech	2x	10.4%	HK$12.4b
BCRX * BioCryst Pharmaceuticals	4.1x	15.5%	Mex$1.6b

Price-To-Sales vs Peers: BCRX * is good value based on its Price-To-Sales Ratio (4.1x) compared to the peer average (16.9x).

Price to Earnings Ratio vs Industry

How does BCRX *'s PE Ratio compare vs other companies in the Global Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	0%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	0%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: BCRX * is good value based on its Price-To-Sales Ratio (4.1x) compared to the Global Biotechs industry average (9.8x).

Price to Sales Ratio vs Fair Ratio

What is BCRX *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BCRX * PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	4.1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BCRX *'s Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.